Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement
Open Access
- 9 October 2009
- journal article
- review article
- Published by Hindawi Limited in International Journal of Clinical Practice
- Vol. 63 (11), 1571-1577
- https://doi.org/10.1111/j.1742-1241.2009.02192.x
Abstract
Basal insulin and premix insulin are commonly prescribed first-line insulin therapies for patients failing to maintain glycaemic control on oral therapy. When control on these insulins starts to drift, premix analogues, such as biphasic insulin aspart 30/70 (BIAsp 30), are a simple and effective tool for intensification as they can be injected up to three-times daily (TID). However, at present, international recommendations for intensification of insulin therapy using premix analogues are limited and specific guidance on dosing is not available for many scenarios. In October 2008, an international expert panel met to review the current guidelines for insulin intensification with BIAsp 30 in patients with type 2 diabetes, with the aim of developing practical guidance for general and specialist practitioners. Simple treatment algorithms have been developed for (i) patients on basal insulin (human or analogue) once daily or twice daily (BID) who need intensification to BIAsp 30 BID, and (ii) patients on BIAsp 30 once daily or BID who can be intensified to BIAsp 30 BID or TID. As well as these algorithms, specific guidance has been provided on dose transfer (from basal insulin to BIAsp 30), dose split (when intensifying from once daily to BID), and combination oral therapies. In addition, a guide to dose titration is included. The guidelines presented here should enable general or specialist practitioners to use BIAsp 30 to intensify the insulin therapy of patients failing on basal insulin or BIAsp 30 once or twice daily.Keywords
This publication has 30 references indexed in Scilit:
- Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix®30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™observational studyInternational Journal of Clinical Practice, 2009
- Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trialDiabetes, Obesity and Metabolism, 2008
- Insulin for type 2 diabetes: choosing a second-line insulin regimenInternational Journal of Clinical Practice, 2008
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT studyInternational Journal of Clinical Practice, 2008
- Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2007
- Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 DiabetesClinical Therapeutics, 2006
- Attainment of glycaemic goals in type 2 diabetes with once‐, twice‐, or thrice‐daily dosing with biphasic insulin aspart 70/30 (The 1‐2‐3 study)Diabetes, Obesity and Metabolism, 2005
- Initiating Insulin Therapy in Type 2 DiabetesDiabetes Care, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998